Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
Proc Natl Acad Sci U S A ; 101(45): 15949-54, 2004 Nov 09.
Article in English | MEDLINE | ID: mdl-15520367

ABSTRACT

Vascular development depends on the highly coordinated actions of a variety of angiogenic regulators, most of which apparently act downstream of vascular endothelial growth factor (VEGF). One potential such regulator is delta-like 4 ligand (Dll4), a recently identified partner for the Notch receptors. We generated mice in which the Dll4 gene was replaced with a reporter gene, and found that Dll4 expression is initially restricted to large arteries in the embryo, whereas in adult mice and tumor models, Dll4 is specifically expressed in smaller arteries and microvessels, with a striking break in expression just as capillaries merge into venules. Consistent with these arterial-specific expression patterns, heterozygous deletion of Dll4 resulted in prominent albeit variable defects in arterial development (reminiscent of those in Notch knockouts), including abnormal stenosis and atresia of the aorta, defective arterial branching from the aorta, and even arterial regression, with occasional extension of the defects to the venous circulation; also noted was gross enlargement of the pericardial sac and failure to remodel the yolk sac vasculature. These striking phenotypes resulting from heterozygous deletion of Dll4 indicate that vascular development may be as sensitive to subtle changes in Dll4 dosage as it is to subtle changes in VEGF dosage, because VEGF accounts for the only other example of haploid insufficiency, resulting in obvious vascular abnormalities. In summary, Dll4 appears to be a major trigger of Notch receptor activities previously implicated in arterial and vascular development, and it may represent a new opportunity for pro- and anti-angiogenic therapies.


Subject(s)
Blood Vessels/abnormalities , Membrane Proteins/deficiency , Membrane Proteins/genetics , Animals , Arteries/abnormalities , Base Sequence , DNA/genetics , Female , Fetal Death/genetics , Gene Expression Regulation, Developmental , Gene Targeting , Genes, Reporter , Heterozygote , Intracellular Signaling Peptides and Proteins , Membrane Proteins/physiology , Mice , Mice, Inbred C57BL , Mice, Knockout , Placenta/abnormalities , Placenta/blood supply , Pregnancy , Vascular Endothelial Growth Factor A/genetics , Vascular Endothelial Growth Factor A/physiology
2.
Nat Biotechnol ; 21(6): 652-9, 2003 Jun.
Article in English | MEDLINE | ID: mdl-12730667

ABSTRACT

One of the most effective approaches for determining gene function involves engineering mice with mutations or deletions in endogenous genes of interest. Historically, this approach has been limited by the difficulty and time required to generate such mice. We describe the development of a high-throughput and largely automated process, termed VelociGene, that uses targeting vectors based on bacterial artificial chromosomes (BACs). VelociGene permits genetic alteration with nucleotide precision, is not limited by the size of desired deletions, does not depend on isogenicity or on positive-negative selection, and can precisely replace the gene of interest with a reporter that allows for high-resolution localization of target-gene expression. We describe custom genetic alterations for hundreds of genes, corresponding to about 0.5-1.0% of the entire genome. We also provide dozens of informative expression patterns involving cells in the nervous system, immune system, vasculature, skeleton, fat and other tissues.


Subject(s)
Chromosomes, Artificial, Bacterial/genetics , Chromosomes, Artificial, Bacterial/metabolism , Gene Expression Profiling/methods , Genetic Engineering/methods , Genome , Animals , Animals, Genetically Modified/genetics , Animals, Genetically Modified/metabolism , Electroporation/methods , Gene Targeting/methods , Mice/genetics , Mutagenesis, Insertional/methods , Mutagenesis, Site-Directed , Quality Control , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Stem Cells/metabolism
3.
Gene ; 308: 31-41, 2003 Apr 10.
Article in English | MEDLINE | ID: mdl-12711388

ABSTRACT

Latent transforming growth factor binding proteins (Ltbp-1, -2, -3 and -4) and fibrillins (Fbn-1 and -2) are structurally related cysteine-rich extracellular matrix proteins that localize to the 10 nm microfibrils. Ltbp-1 is thought to promote the secretion and proper folding of the small latent transforming growth factor beta (TGF-beta) complex (TGF-beta plus its propeptide) and is implicated in sequestering it in the extracellular matrix. Here we report the isolation of the mouse Ltbp-1 complementary DNA (cDNA) and gene. The longer form of the Ltbp-1 cDNA encodes a predicted 1713 amino acid protein containing 18 epidermal growth factor-like repeats, four 8-cysteine domains and several motifs that suggest interactions with alpha(IV)beta(1) and alpha(9)beta(1) integrins. Northern blotting analyses indicate that long and short Ltbp-1 transcripts are widely expressed in adult mouse tissues and most abundantly expressed in heart. Ltbp-1 is a single copy gene that maps to chromosome 17, band E (1-3) and encompasses more than 212 kb. The Ltbp-1 gene contains 34 exons and shows a similar organization to the LTBP-2 gene, suggesting that these genes originated from a common ancestral gene.


Subject(s)
Alternative Splicing , Carrier Proteins/genetics , Intracellular Signaling Peptides and Proteins , Amino Acid Sequence , Animals , Base Sequence , Blotting, Northern , Chromosome Mapping , Cloning, Molecular , DNA/chemistry , DNA/genetics , DNA, Complementary/genetics , Exons , Gene Expression , Genes/genetics , In Situ Hybridization, Fluorescence , Introns , Latent TGF-beta Binding Proteins , Mice , Mice, Inbred Strains , Molecular Sequence Data , Protein Isoforms/genetics , RNA, Messenger/genetics , RNA, Messenger/metabolism , Sequence Analysis, DNA
SELECTION OF CITATIONS
SEARCH DETAIL